Biotech News
Related news
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
AVIRAtea2026-06-25 11:00 EST
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
ANTXAN2 Therapeutics2026-06-04 11:00 EST
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
SCYXSCYNEXIS2026-06-30 12:00 EST
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ASMBAssembly Biosciences2026-05-13 06:00 EST
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
IMNNImunon2025-11-07 13:05 EST
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
IMNNImunon2025-11-10 12:30 EST
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
Atea
Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers...
Recent company news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
AVIRAtea2026-06-25 11:00 EST
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
AVIRAtea2026-05-27 11:00 EST
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Stock data
- Close
- 4.99 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States